



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Center - WO66-G609  
Silver Spring, MD 20993-0002

Restore Surgical LLC, dba Instratek  
Mr. Jeff Seavey  
President  
15200 Middlebrook Drive, Suite G  
Houston, Texas 77058

February 10, 2017

Re: K162321

Trade/Device Name: EasyClip Xpress  
Regulation Number: 21 CFR 888.3030  
Regulation Name: Single/multiple component metallic bone fixation appliances and accessories  
Regulatory Class: Class II  
Product Code: JDR  
Dated: January 12, 2017  
Received: January 13, 2017

Dear Mr. Seavey:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in

the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely,

**Mark N. Melkerson -S**

Mark N. Melkerson  
Director  
Division of Orthopedic Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**SECTION 006: INDICATIONS FOR USE STATEMENT**

**510(k) Number: K162321**

**Device Name:** EasyClip Xpress

**Indications for Use:**

The EasyClip Xpress Staples are indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Restore Surgical LLC, dba Instratek

**SECTION 007: 510(K) SUMMARY**

<b>Submission Correspondent and Owner:</b>	Restore Surgical LLC, dba Instratek 15200 Middlebrook Dr., Suite G Houston, TX 77058 USA  Phone: 281-890-8020 Fax: 281-890-8068 Email: jeff@instratek.com Contact: Mr. Jeff Seavey President
<b>Date summary prepared:</b>	August 11, 2016
<b>Device trade name:</b>	EasyClip Xpress
<b>Device classification name:</b>	Staple, Fixation, Bone
<b>Classification:</b>	Class II
<b>Product Code:</b>	JDR
<b>Regulation/Description:</b>	880.3030, Staple, Fixation, Bone
<b>Predicate Devices</b>	Stapix Superelastic Nitinol Fixation System (K133523) Stryker Memory Staple (K122113).
<b>Description of the device:</b>	EasyClip Xpress is comprised of superelastic bone staples, as well as associated instrumentation required for implantation of the staples.
<b>Intended use of the device:</b>	The EasyClip Xpress is indicated for hand and foot bone fragments osteotomy fixation and joint arthrodesis.
<b>Technological characteristics:</b>	The proposed device has the same design, material, and intended use as the predicate devices.
<b>Testing:</b>	Dimensional (geometric cross section) and engineering strength analyses as well as static and dynamic bending tests were conducted initially in K122113 and the results support the conclusion that there are no effects of the modifications subject to this premarket notification on the safety and effectiveness of the EasyClip staples. Other testing performed: Corrosion Testing as per ASTM F2129, Bacterial Endotoxins Test (LAL testing has been performed to establish that the subject device meets the specified 20 EU/device limit).
<b>Conclusions:</b>	The results of the comparison of design, materials, intended use and technological characteristics demonstrate that the device is as safe and effective as the legally marketed predicate devices.